$249 Million is the total value of TCG Crossover Management, LLC's 20 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISEE | Buy | Iveric Bio, Inc. | $42,360,000 | +45.5% | 2,516,920 | +44.5% | 17.00% | +24.7% |
| VRDN | Viridian Therapeutics Inc | $24,296,000 | -6.5% | 1,314,000 | 0.0% | 9.75% | -19.8% | |
| COGT | Buy | Cogent Biosciences, Inc. | $22,328,000 | -5.4% | 2,981,042 | +8.4% | 8.96% | -18.9% |
| ACRS | Buy | Aclaris Therapeuitics, Inc. | $19,739,000 | +25.4% | 1,144,939 | +5.8% | 7.92% | +7.5% |
| GERN | New | Geron Corporation | $19,429,000 | – | 14,285,715 | +100.0% | 7.80% | – |
| CBAY | CymaBay Therapeutics, Inc. | $18,366,000 | -8.0% | 5,905,400 | 0.0% | 7.37% | -21.1% | |
| AVTE | Buy | Aerovate Therapeutics, Inc. | $16,306,000 | +62.1% | 889,572 | +4.2% | 6.55% | +39.0% |
| KDNY | Chinook Therapeutics, Inc. | $14,435,000 | +0.3% | 882,353 | 0.0% | 5.80% | -14.0% | |
| Buy | Tyra Biosciences, Inc. | $9,592,000 | -19.8% | 896,418 | +5.4% | 3.85% | -31.3% | |
| New | Tango Therapeutics, Inc. | $9,509,000 | – | 1,254,500 | +100.0% | 3.82% | – | |
| ALPN | Sell | Alpine Immune Sciences, Inc. | $9,277,000 | -42.8% | 1,034,222 | -11.6% | 3.72% | -50.9% |
| KURA | New | Kura Oncology, Inc. | $8,143,000 | – | 506,423 | +100.0% | 3.27% | – |
| MRUS | Buy | Merus N.V. | $7,932,000 | +10.9% | 300,000 | +33.3% | 3.18% | -5.0% |
| AKUS | Buy | Akouos, Inc. | $6,413,000 | -27.8% | 1,350,006 | +29.2% | 2.57% | -38.1% |
| MGTA | Sell | Magenta Therapeutics, Inc. | $6,160,000 | -37.4% | 2,124,122 | -4.4% | 2.47% | -46.3% |
| Entrada Therapeutics, Inc. | $6,133,000 | -46.0% | 663,694 | 0.0% | 2.46% | -53.7% | ||
| ZLAB | Zai Lab LTD-ADR | $4,178,000 | -30.0% | 95,000 | 0.0% | 1.68% | -40.0% | |
| New | Pardes Biosciences, Inc. | $1,654,000 | – | 229,100 | +100.0% | 0.66% | – | |
| ANAB | New | AnaptysBio, Inc. | $1,448,000 | – | 58,515 | +100.0% | 0.58% | – |
| ELEV | Elevation Oncology, Inc. | $1,399,000 | -58.1% | 555,000 | 0.0% | 0.56% | -64.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
| AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
| TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
| ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
| MERUS N.V. | 8 | Q3 2023 | 3.4% |
| IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
| Geron Corporation | 7 | Q3 2023 | 12.4% |
| ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
| KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
| CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
| Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
| Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
| Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| SC 13G | 2022-08-19 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-18 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.